|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
PT1912636E
(en)
*
|
2005-07-21 |
2014-07-24 |
Ardea Biosciences Inc |
N-(arylamino)-sulfonamide inhibitors of mek
|
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
JO2985B1
(en)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
MAPK/ERK Kinase Inhibitors
|
|
ES2320955B1
(en)
|
2007-03-02 |
2010-03-16 |
Laboratorios Almirall S.A. |
NEW DERIVATIVES OF 3 - ((1,2,4) TRIAZOLO (4,3-A) PIRIDIN-7-IL) BENZAMIDA.
|
|
US8063066B2
(en)
|
2007-03-19 |
2011-11-22 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
ES2329639B1
(en)
|
2007-04-26 |
2010-09-23 |
Laboratorios Almirall S.A. |
NEW DERIVATIVES OF 4,8-DIFENILPOLIAZANAFTALENO.
|
|
EP2172198B1
(en)
|
2007-07-20 |
2014-04-16 |
Chugai Seiyaku Kabushiki Kaisha |
p27 PROTEIN INDUCER
|
|
EP2227469B9
(en)
*
|
2007-11-12 |
2014-09-10 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
US20090246198A1
(en)
*
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
EP2108641A1
(en)
|
2008-04-11 |
2009-10-14 |
Laboratorios Almirall, S.A. |
New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
|
|
EP2113503A1
(en)
|
2008-04-28 |
2009-11-04 |
Laboratorios Almirall, S.A. |
New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
RU2393157C1
(en)
*
|
2008-10-06 |
2010-06-27 |
Андрей Александрович Иващенко |
2-ALKYLAMINO-3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS
|
|
RU2399621C2
(en)
*
|
2008-10-14 |
2010-09-20 |
Андрей Александрович Иващенко |
SUBSTITUTED 2-ALKYLMINO-3-SULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
EP2362775B1
(en)
|
2008-11-20 |
2015-08-05 |
GlaxoSmithKline LLC |
Chemical compounds
|
|
JP5651125B2
(en)
|
2008-12-10 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
MEK mutations that confer resistance to MEK inhibitors
|
|
WO2010109468A1
(en)
|
2009-03-26 |
2010-09-30 |
Mapi Pharma Hk Limited |
Process for the preparation of alogliptin
|
|
CN101619063B
(en)
*
|
2009-06-02 |
2011-08-10 |
华中师范大学 |
3,7,8-polysubstituted pyridine-[4,3-d] pyrimidine derivant with antitumor activity and preparation
|
|
WO2011031308A1
(en)
*
|
2009-09-09 |
2011-03-17 |
Cytokinetics, Incorporated |
Novel combinations
|
|
EA201270453A1
(en)
*
|
2009-09-23 |
2013-12-30 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
COMBINATION
|
|
US20120322817A1
(en)
*
|
2009-09-23 |
2012-12-20 |
Melissa Dumble |
Combination
|
|
WO2011038380A2
(en)
*
|
2009-09-28 |
2011-03-31 |
Glaxosmithkline Llc |
Combination
|
|
EA022982B1
(en)
*
|
2009-10-08 |
2016-04-29 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Combination for treating cancer and/or pre-cancerous syndromes
|
|
EA020589B1
(en)
|
2009-10-16 |
2014-12-30 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
TREATMENT COMBINATION
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011047795A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
CN102574782B
(en)
|
2009-10-21 |
2014-10-08 |
拜耳知识产权有限责任公司 |
Substituted halophenoxybenzamide derivatives
|
|
US20120283279A1
(en)
*
|
2009-11-17 |
2012-11-08 |
Glaxosmithkline Llc |
Combination
|
|
MX360932B
(en)
|
2010-02-25 |
2018-11-21 |
Dana Farber Cancer Inst Inc |
Braf mutations conferring resistance to braf inhibitors.
|
|
RU2421456C1
(en)
*
|
2010-02-26 |
2011-06-20 |
Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" |
SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINE-2,6-DIAMINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS
|
|
MX343368B
(en)
|
2010-03-09 |
2016-11-01 |
The Broad Inst Inc * |
Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy.
|
|
UY33288A
(en)
*
|
2010-03-25 |
2011-10-31 |
Glaxosmithkline Llc |
INDOLINE DERIVATIVES INHIBITORS OF THE PROTEIN QUINASA R OF THE ENDOPLASMATIC RETICLE
|
|
BR112012024380A2
(en)
|
2010-03-25 |
2015-09-15 |
Glaxosmithkline Llc |
chemical compounds
|
|
CN102869358B
(en)
*
|
2010-04-13 |
2016-03-23 |
诺华股份有限公司 |
Combinations comprising a cyclin-dependent kinase 4 or cyclin-dependent kinase 6 (CDK4/6) inhibitor and an mTOR inhibitor for the treatment of cancer
|
|
JP5858989B2
(en)
|
2010-05-21 |
2016-02-10 |
ノバルティス アーゲー |
combination
|
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
|
WO2012027438A1
(en)
|
2010-08-26 |
2012-03-01 |
Glaxosmithkline Llc |
Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
|
|
EP2632899A1
(en)
|
2010-10-29 |
2013-09-04 |
Bayer Intellectual Property GmbH |
Substituted phenoxypyridines
|
|
CN102020651B
(en)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
|
|
EP2635286A4
(en)
*
|
2010-11-05 |
2014-11-12 |
Glaxosmithkline Ip No 2 Ltd |
METHODS OF TREATING CANCER
|
|
JP2013545757A
(en)
*
|
2010-11-17 |
2013-12-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド |
How to treat cancer
|
|
BR112013012485A2
(en)
*
|
2010-11-19 |
2016-09-06 |
Glaxosmithkline Ip No 2 Ltd |
braf inhibitor treatment method
|
|
US8906879B2
(en)
|
2010-12-20 |
2014-12-09 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Combination for the treatment of cancer
|
|
TWI505828B
(en)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產（第二）有限公司 |
Novel pharmaceutical composition
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2013019620A2
(en)
*
|
2011-07-29 |
2013-02-07 |
Glaxosmithkline Llc |
Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
|
|
BR112014002353B1
(en)
*
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT
|
|
KR20140072028A
(en)
|
2011-08-31 |
2014-06-12 |
노파르티스 아게 |
Synergistic combinations of pi3k- and mek-inhibitors
|
|
ES2661510T3
(en)
|
2011-12-15 |
2018-04-02 |
Novartis Ag |
Use of inhibitors of PI3K activity or function
|
|
ES2684517T3
(en)
*
|
2012-03-14 |
2018-10-03 |
Lupin Limited |
Heterocyclyl compounds as MEK inhibitors
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
NZ702747A
(en)
|
2012-06-13 |
2017-03-31 |
Incyte Holdings Corp |
Substituted tricyclic compounds as fgfr inhibitors
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
BR112015004578A2
(en)
|
2012-09-04 |
2017-07-04 |
Glaxosmithkline Llc |
methods for providing adjuvant treatment to a patient with an earlier diagnosis of melanoma that has been resected and to increase relapse-free survival (rfs) of a patient following melanoma resection;
|
|
CA2889530A1
(en)
*
|
2012-10-25 |
2014-05-01 |
Glaxosmithkline Llc |
Combination
|
|
ES2669248T3
(en)
|
2012-11-29 |
2018-05-24 |
Novartis Ag |
Pharmaceutical combinations
|
|
JP6232443B2
(en)
*
|
2012-11-30 |
2017-11-15 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
Novel pharmaceutical composition
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
KR20150103735A
(en)
|
2013-01-09 |
2015-09-11 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
Combination
|
|
ES2703208T3
(en)
|
2013-02-27 |
2019-03-07 |
Daiichi Sankyo Co Ltd |
Method for predicting sensitivity to a compound that inhibits the MAPK signal transduction pathway
|
|
LT2986610T
(en)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AR096433A1
(en)
|
2013-05-28 |
2015-12-30 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
METHOD OF CANCER TREATMENT AND USE
|
|
JP2016520643A
(en)
|
2013-06-03 |
2016-07-14 |
ノバルティス アーゲー |
Combination of anti-PD-L1 antibody and MEK inhibitor and / or BRAF inhibitor
|
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
US9914703B2
(en)
*
|
2013-10-25 |
2018-03-13 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
|
|
WO2015059677A1
(en)
|
2013-10-26 |
2015-04-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer
|
|
WO2015081566A1
(en)
*
|
2013-12-06 |
2015-06-11 |
杭州普晒医药科技有限公司 |
Crystalline forms of trametinib and solvate thereof, preparation method therefor, pharmaceutical composition comprising same and use thereof
|
|
AU2014362995A1
(en)
|
2013-12-12 |
2016-05-26 |
Novartis Ag |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
TIM-3 Antibody Molecules and Their Uses
|
|
EP2913048A1
(en)
*
|
2014-02-27 |
2015-09-02 |
ratiopharm GmbH |
Pharmaceutical composition comprising trametinib
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
WO2016009306A1
(en)
|
2014-07-15 |
2016-01-21 |
Lupin Limited |
Heterocyclyl compounds as mek inhibitors
|
|
CN116617401A
(en)
|
2014-07-15 |
2023-08-22 |
豪夫迈·罗氏有限公司 |
Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors
|
|
WO2016035008A1
(en)
|
2014-09-04 |
2016-03-10 |
Lupin Limited |
Pyridopyrimidine derivatives as mek inhibitors
|
|
EP3191127A1
(en)
|
2014-09-13 |
2017-07-19 |
Novartis AG |
Combination therapies of egfr inhibitors
|
|
EP3200775B1
(en)
|
2014-10-03 |
2019-11-20 |
Novartis AG |
Combination therapies
|
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
PE20171067A1
(en)
|
2014-10-14 |
2017-07-24 |
Novartis Ag |
ANTIBODY MOLECULES BINDING AND USES OF PD-L1
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
SG10201913036RA
(en)
|
2015-02-20 |
2020-02-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
|
JP2016155776A
(en)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
Antitumor effect enhancer and antitumor agent
|
|
CZ2015278A3
(en)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Trametinib crystalline forms
|
|
CN114272371A
(en)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
Combination therapy containing anti-PD-1 antibody molecules
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
JP2018526377A
(en)
|
2015-08-28 |
2018-09-13 |
ノバルティス アーゲー |
Combination of CDK4 / 6 inhibitor LEE011 and MEK1 / 2 inhibitor trametinib, optionally further comprising PI3K inhibitor BYL719 for the treatment of cancer
|
|
WO2017037579A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
CN108697791B
(en)
|
2015-11-03 |
2022-08-23 |
詹森生物科技公司 |
Antibodies that specifically bind to PD-1 and uses thereof
|
|
RU2605400C1
(en)
*
|
2015-11-13 |
2016-12-20 |
ЗАО "Р-Фарм" |
DERIVATIVES OF 1-(3-AMINOPHENYL)-6,8-DIMETHYL-5-(4-IODO-2-FLUORO-PHENYLAMINO)-3-CYCLOPROPYL-1H,6H-PYRIDO[4,3-d]PYRIMIDINE-2,4,7-TRIONE AS MEK1/2 INHIBITORS
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
MX2018007423A
(en)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof.
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
AU2017226389B2
(en)
|
2016-03-04 |
2023-02-02 |
Taiho Pharmaceutical Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
ES2974991T3
(en)
|
2016-09-19 |
2024-07-02 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and an ERK inhibitor
|
|
RU2627692C1
(en)
*
|
2016-10-10 |
2017-08-10 |
Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") |
N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidine-1-il]-phenyl}-cyclopropanecarboxamide dimethylsulfoxide solvate as mek1/2 inhibitor
|
|
CN107970246B
(en)
*
|
2016-10-21 |
2020-08-28 |
中山大学 |
Application of non-steroidal anti-inflammatory drugs in enhancing the sensitivity of tumor cells to tyrosine kinase inhibitors
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
KR101892457B1
(en)
|
2016-11-25 |
2018-08-31 |
주식회사 샤인바이오 |
Composition for promoting and protecting the differentiation of neural stem cells and a method for inducing neural regeneration using the same
|
|
CN110225983A
(en)
|
2016-12-01 |
2019-09-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
The method for the treatment of cancer
|
|
FI3618875T3
(en)
|
2017-05-02 |
2023-07-04 |
Novartis Ag |
COMBINATION THERAPY WITH A RAF INHIBITOR AND TRAMETINIB
|
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
|
TW201922721A
(en)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
Chemical compounds
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
KR20200089286A
(en)
|
2017-11-16 |
2020-07-24 |
노파르티스 아게 |
Combination therapy
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
SG11202008435SA
(en)
|
2018-03-19 |
2020-10-29 |
Taiho Pharmaceutical Co Ltd |
Pharmaceutical composition including sodium alkyl sulfate
|
|
WO2019180141A1
(en)
|
2018-03-23 |
2019-09-26 |
Bayer Aktiengesellschaft |
Combinations of rogaratinib
|
|
EP3773586A1
(en)
|
2018-03-30 |
2021-02-17 |
Novartis AG |
A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
|
|
EP3560516A1
(en)
|
2018-04-27 |
2019-10-30 |
Bergen Teknologioverforing AS |
Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
|
|
EP4309737A3
(en)
|
2018-05-04 |
2024-03-27 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
EP3788046B1
(en)
|
2018-05-04 |
2025-12-10 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
|
PE20211916A1
(en)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
BINDING AGENTS OF PSMA AND USES OF THEM
|
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
|
EP3867409A1
(en)
|
2018-10-16 |
2021-08-25 |
Novartis AG |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
CN109320513B
(en)
*
|
2018-11-09 |
2021-03-16 |
安庆奇创药业有限公司 |
Method for synthesizing trametinib
|
|
CN113473978B
(en)
|
2018-11-20 |
2025-03-28 |
恩福莱克逊治疗有限公司 |
Cyanoarene-aniline compounds for the treatment of skin diseases
|
|
JP7393808B2
(en)
*
|
2018-11-20 |
2023-12-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
Naphthyridinone-aniline compounds for the treatment of skin disorders
|
|
CA3120352A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
TWI824069B
(en)
|
2018-11-30 |
2023-12-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
Compounds useful in hiv therapy
|
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2020161654A1
(en)
*
|
2019-02-06 |
2020-08-13 |
Aurobindo Pharma Limited |
A process for the preparation of trametinib acetic acid solvate
|
|
MX2021009764A
(en)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
3-(1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONA SUBSTITUTE DERIVATIVES AND USES THEREOF.
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
AR118720A1
(en)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
METHODS FOR TREATING PROSTATE CANCER WITH AN ANTI-PSMA / CD3 ANTIBODY
|
|
MX2021013817A
(en)
|
2019-05-13 |
2021-12-14 |
Novartis Ag |
NEW CRYSTALLINE FORMS OF N-(3-(2-(2-HYDROXYETOXY)-6-MORPHOLINOP IRIDIN-4-IL)-4-METHYLPHENYL)-2-(TRIFLUOROMETHYL)SONICOTINAMIDE AS RAF INHIBITORS FOR THE TREATMENT OF CANCER.
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021018112A1
(en)
*
|
2019-07-29 |
2021-02-04 |
江苏恒瑞医药股份有限公司 |
Preparation method of 1,6-dihydropyridine-3-carboxamide derivative
|
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CR20220169A
(en)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
KR20220131900A
(en)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Derivatives of FGFR inhibitors
|
|
CN115175937A
(en)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
Combination of anti-TIM-3 antibody MBG453 and anti-TGF-beta antibody NIS793 with or without decitabine or anti-PD-1 antibody, gabapentin, for the treatment of myelofibrosis and myelodysplastic syndrome
|
|
US20230381180A1
(en)
*
|
2020-01-08 |
2023-11-30 |
Icahn School Of Medicine At Mount Sinai |
Small molecule modulators of ksr-bound mek
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US20230226030A1
(en)
|
2020-02-18 |
2023-07-20 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
|
|
US20230165862A1
(en)
|
2020-04-10 |
2023-06-01 |
Taiho Pharmaceutical Co., Ltd. |
Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
|
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
|
JP2023525100A
(en)
|
2020-05-12 |
2023-06-14 |
ノバルティス アーゲー |
Therapeutic combinations containing CRAF inhibitors
|
|
AU2021285032A1
(en)
*
|
2020-06-02 |
2022-12-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4203963B1
(en)
|
2020-08-31 |
2026-01-21 |
Novartis AG |
Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
|
|
KR20230131189A
(en)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
TEAD inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3205726A1
(en)
|
2021-01-25 |
2022-07-28 |
Alfredo C. Castro |
Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
|
|
EP4284838A2
(en)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
CA3206906A1
(en)
|
2021-02-02 |
2022-08-11 |
Andras Herner |
Selective bcl-xl protac compounds and methods of use
|
|
CN117321418A
(en)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
Cancer biomarkers and how to use them
|
|
TWI825637B
(en)
*
|
2021-03-31 |
2023-12-11 |
美商輝瑞股份有限公司 |
3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
|
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
|
US20240238294A1
(en)
|
2021-04-09 |
2024-07-18 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
US12065494B2
(en)
|
2021-04-12 |
2024-08-20 |
Incyte Corporation |
Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
|
|
WO2022221866A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US20240238284A1
(en)
|
2021-05-05 |
2024-07-18 |
Novartis Ag |
Compounds and compositions for the treatment of mpnst
|
|
AR125874A1
(en)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
COMBINATION THERAPIES
|
|
AR126101A1
(en)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
|
AR126102A1
(en)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
|
WO2022259157A1
(en)
|
2021-06-09 |
2022-12-15 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
TW202342766A
(en)
|
2022-03-02 |
2023-11-01 |
瑞士商諾華公司 |
Precision therapy for the treatment of cancer
|
|
CN114573582B
(en)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
1,2,3, 4-tetrahydropyrido [2,3-d ] pyrimidine compound and preparation method and application thereof
|
|
CN114573581B
(en)
*
|
2022-03-30 |
2023-09-01 |
沈阳药科大学 |
5-substituted amino-1, 3-disubstituted phenylpyrido [2,3-d ] pyrimidine compound and preparation and application thereof
|
|
CN114456166B
(en)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
5-substituted amino-3-methylpyrido [2,3-d ] pyrimidine compound and preparation and application thereof
|
|
CN114605408B
(en)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
5-hydroxy-1, 3-disubstituted phenylpyrido [2,3-d ] pyrimidine compound and preparation method and application thereof
|
|
KR20250027281A
(en)
|
2022-05-20 |
2025-02-25 |
노파르티스 아게 |
EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of use thereof
|
|
AU2023273734A1
(en)
|
2022-05-20 |
2024-12-12 |
Les Laboratoires Servier |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
CN114853754B
(en)
*
|
2022-05-23 |
2023-04-18 |
云白药征武科技(上海)有限公司 |
Thioamide derivative and preparation method and application thereof
|
|
AU2023276599A1
(en)
|
2022-05-25 |
2024-12-05 |
Imagenebio, Inc. |
Mek inhibitors and uses thereof
|
|
AR129423A1
(en)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
USEFUL COMPOUNDS IN HIV THERAPY
|
|
CN120752058A
(en)
|
2023-03-10 |
2025-10-03 |
诺华股份有限公司 |
PanRAS inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
WO2025132408A2
(en)
|
2023-12-21 |
2025-06-26 |
Synthon B.V. |
Solvates of trametinib
|
|
WO2025132190A1
(en)
|
2023-12-22 |
2025-06-26 |
Synthon B.V. |
A process for making trametinib
|
|
WO2025146444A1
(en)
|
2024-01-03 |
2025-07-10 |
Bayer Aktiengesellschaft |
Darolutamide in combination with braf and mek inhibitors for melanoma treatment
|
|
CN120441478A
(en)
*
|
2024-02-07 |
2025-08-08 |
成都赜灵生物医药科技有限公司 |
A six-membered lactam compound and its application
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
CN118121604B
(en)
*
|
2024-05-07 |
2024-06-25 |
四川成都中农大现代农业产业研究院 |
Composition of epigallocatechin gallate and application of composition as copper ion carrier anti-liver cancer sensitizer
|